









Markets
/
Stocks
/
nasdaq-qgen
/

Qiagen NV

QGEN

46.561USD

-0.629-1.33%

Market hours （ET）Quotes delayed by 15 min

10.10BMarket Cap

27.04P/E TTM



Qiagen NV

46.561

-0.629-1.33%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Qiagen NV

Currency: USD Updated: 2025-10-29

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Qiagen NV's Score

Industry at a Glance

Industry Ranking

11 / 407

Overall Ranking

64 / 4623

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 18 analysts

Buy

Current Rating

51.073

Target Price

+6.51%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Qiagen NV Highlights

StrengthsRisks

Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.

Fairly Valued

The company’s latest PE is 27.43, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 196.38M shares, decreasing 6.05% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 5.37K shares of this stock.

Financial Health

Currency: USD Updated: 2025-10-29

The company's current financial score is 9.38, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 533.54M, representing a year-over-year increase of 7.49%, while its net profit experienced a year-over-year increase of 152.46%.

Score

Industry at a Glance

Previous score

9.38

Change



Financials

9.72

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

9.40

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.80

Key Metrics

Free cash flow

No Data

Qiagen NV's Company Valuation

Currency: USD Updated: 2025-10-29

The company’s current valuation score is 7.22, which is higher than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is 27.43, which is 368.43% below the recent high of 128.51 and 18.74% above the recent low of 22.29.

Score

Industry at a Glance

Previous score

7.22

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 11/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-29

The company’s current earnings forecast score is 7.11, which is lower than the Biotechnology & Medical Research industry's average of 8.01. The average price target for Qiagen NV is 50.07, with a high of 57.00 and a low of 45.00.

Score

Industry at a Glance

Previous score

7.11

Change

Support & Resistance

No Data

Analyst Rating

Based on 18 analysts

Buy

Current Rating

51.073

Target Price

+8.23%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

520

Total

Median

Average

Company name

Ratings

Analysts

Qiagen NV

QGEN

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-29

The company’s current price momentum score is 6.90, which is higher than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 49.17 and the support level at 45.62, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.94

Change

-2.04

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.054

Neutral

RSI(14)

46.859

Neutral

STOCH(KDJ)(9,3,3)

27.434

Sell

ATR(14)

0.805

Low Volatility

CCI(14)

-83.242

Neutral

Williams %R

76.433

Sell

TRIX(12,20)

0.236

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

48.442

Sell

MA10

48.443

Sell

MA20

47.750

Sell

MA50

46.978

Sell

MA100

47.703

Sell

MA200

44.737

Buy

Institutional Confidence

Currency: USD Updated: 2025-10-29

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.21. The latest institutional shareholding proportion is 90.57%, representing a quarter-over-quarter increase of 3.47%. The largest institutional shareholder is The Vanguard, holding a total of 9.16M shares, representing 4.22% of shares outstanding, with 6.88% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Wellington Management Company, LLP

26.02M

+6.49%

MFS Investment Management

23.48M

-3.24%

The Vanguard Group, Inc.

Star Investors

9.16M

+4.24%

T. Rowe Price International Ltd

5.94M

+43.10%

EARNEST Partners, LLC

4.20M

+10.39%

Amundi Asset Management, SAS

3.98M

-5.19%

Boston Partners

2.36M

+0.58%

DWS Investment GmbH

3.30M

+482.72%

Swedbank Robur Fonder AB

3.30M

-0.51%

Risk Assessment

Currency: USD Updated: 2025-10-29

The company’s current risk assessment score is 9.14, which is higher than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 0.65. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.